I believe that discussions with CDER over the trial architecture may have involved the possibility of a "Basket Trial" expansion covering one or more of the Orphan Diseases of Fragile X, Angelman's and Infantile Spasms in future
You seem to be saying that Anavex pulled the IND rather than the FDA requiring modifications? If that were indeed the case, then Anavex would have benefited from issuing a PR to that effect, wouldn’t they. A missed opportunity?
Does Missling need to add more corporate officers to improve operational communication? Is it normal for BOD members to receive zero monetary compensation?
Market Data 
Markets 
AI
